Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment

Abstract Background Hepatocellular carcinoma is a highly prevalent tumor worldwide. Amphiregulin is a ligand of the epidermal growth factor receptor. Its elevation is linked to different inflammatory and neoplastic conditions. Therefore, amphiregulin may represent a potential diagnostic target in HC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amira Isaac, Sherif Mounir Mohamed, Osama Ashraf Ahmed, Ahmed Gamal Mohamed Hassan, Hany Samir Rasmy
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	Amphiregulin Hepatocellular carcinoma Radiofrequency ablation Transarterial chemoembolization Internal medicine RC31-1245
Acceso en línea:	https://doaj.org/article/7eb938a4cc2b4c24b7e6e32a4cc6c076
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7eb938a4cc2b4c24b7e6e32a4cc6c076
record_format	dspace
spelling	oai:doaj.org-article:7eb938a4cc2b4c24b7e6e32a4cc6c0762021-11-14T12:05:44ZAmphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment10.1186/s43162-021-00078-51110-77822090-9098https://doaj.org/article/7eb938a4cc2b4c24b7e6e32a4cc6c0762021-11-01T00:00:00Zhttps://doi.org/10.1186/s43162-021-00078-5https://doaj.org/toc/1110-7782https://doaj.org/toc/2090-9098Abstract Background Hepatocellular carcinoma is a highly prevalent tumor worldwide. Amphiregulin is a ligand of the epidermal growth factor receptor. Its elevation is linked to different inflammatory and neoplastic conditions. Therefore, amphiregulin may represent a potential diagnostic target in HCC, which has sparked interest as a potential predictor of diagnosis and progression of HCC. The current work was set out to evaluate amphiregulin as a possible diagnostic and prognostic biomarker for HCC on top of cirrhosis. Thirty adult patients with liver cirrhosis and HCC (HCC group) were randomly selected as candidates for locoregional therapies, either radiofrequency ablation or transarterial chemoembolization. A separate group of thirty liver cirrhosis patients served as controls (cirrhosis group). All patients underwent standard laboratory tests and abdominal ultrasounds. Alpha-fetoprotein and amphiregulin were measured twice at baseline and 1 month after the intervention. Results Baseline serum amphiregulin was significantly higher in the HCC group than in the cirrhosis group (23.2 ± 11.5 vs. 11.1 ± 7.1), with a p value < 0.001. Patients with multiple and larger focal lesions had greater levels of amphiregulin, with p values of 0.015 and 0.002, respectively. At 1 month following locoregional treatment, the amphiregulin level considerably declined compared with its baseline levels (from 23.2 ± 11.5 to 19.4 ± 10.9), with a p value of 0.012, while AFP showed an insignificant reduction. At follow-up, the level of serum amphiregulin was statistically significantly greater in recurrence cases than in remission cases (30.8 ± 14.1 vs. 17.2 ± 8.8), with a p value of 0.008, and the same was observed for AFP level. At a cutoff ≥ 17 pg/mL, amphiregulin was a valuable marker in HCC detection with a sensitivity and specificity of 63.3% and 86.7%, respectively, while it has 60% sensitivity and 96% specificity in detecting possible tumor recurrence at a cutoff ≥ 29.7 pg/ml. Conclusions Amphiregulin may be a good diagnostic marker for HCC and a prognostic marker after locoregional therapies because its follow-up levels are useful in predicting possible tumor recurrence.Amira IsaacSherif Mounir MohamedOsama Ashraf AhmedAhmed Gamal Mohamed HassanHany Samir RasmySpringerOpenarticleAmphiregulinHepatocellular carcinomaRadiofrequency ablationTransarterial chemoembolizationInternal medicineRC31-1245ENThe Egyptian Journal of Internal Medicine, Vol 33, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Amphiregulin Hepatocellular carcinoma Radiofrequency ablation Transarterial chemoembolization Internal medicine RC31-1245
spellingShingle	Amphiregulin Hepatocellular carcinoma Radiofrequency ablation Transarterial chemoembolization Internal medicine RC31-1245 Amira Isaac Sherif Mounir Mohamed Osama Ashraf Ahmed Ahmed Gamal Mohamed Hassan Hany Samir Rasmy Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
description	Abstract Background Hepatocellular carcinoma is a highly prevalent tumor worldwide. Amphiregulin is a ligand of the epidermal growth factor receptor. Its elevation is linked to different inflammatory and neoplastic conditions. Therefore, amphiregulin may represent a potential diagnostic target in HCC, which has sparked interest as a potential predictor of diagnosis and progression of HCC. The current work was set out to evaluate amphiregulin as a possible diagnostic and prognostic biomarker for HCC on top of cirrhosis. Thirty adult patients with liver cirrhosis and HCC (HCC group) were randomly selected as candidates for locoregional therapies, either radiofrequency ablation or transarterial chemoembolization. A separate group of thirty liver cirrhosis patients served as controls (cirrhosis group). All patients underwent standard laboratory tests and abdominal ultrasounds. Alpha-fetoprotein and amphiregulin were measured twice at baseline and 1 month after the intervention. Results Baseline serum amphiregulin was significantly higher in the HCC group than in the cirrhosis group (23.2 ± 11.5 vs. 11.1 ± 7.1), with a p value < 0.001. Patients with multiple and larger focal lesions had greater levels of amphiregulin, with p values of 0.015 and 0.002, respectively. At 1 month following locoregional treatment, the amphiregulin level considerably declined compared with its baseline levels (from 23.2 ± 11.5 to 19.4 ± 10.9), with a p value of 0.012, while AFP showed an insignificant reduction. At follow-up, the level of serum amphiregulin was statistically significantly greater in recurrence cases than in remission cases (30.8 ± 14.1 vs. 17.2 ± 8.8), with a p value of 0.008, and the same was observed for AFP level. At a cutoff ≥ 17 pg/mL, amphiregulin was a valuable marker in HCC detection with a sensitivity and specificity of 63.3% and 86.7%, respectively, while it has 60% sensitivity and 96% specificity in detecting possible tumor recurrence at a cutoff ≥ 29.7 pg/ml. Conclusions Amphiregulin may be a good diagnostic marker for HCC and a prognostic marker after locoregional therapies because its follow-up levels are useful in predicting possible tumor recurrence.
format	article
author	Amira Isaac Sherif Mounir Mohamed Osama Ashraf Ahmed Ahmed Gamal Mohamed Hassan Hany Samir Rasmy
author_facet	Amira Isaac Sherif Mounir Mohamed Osama Ashraf Ahmed Ahmed Gamal Mohamed Hassan Hany Samir Rasmy
author_sort	Amira Isaac
title	Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
title_short	Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
title_full	Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
title_fullStr	Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
title_full_unstemmed	Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
title_sort	amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/7eb938a4cc2b4c24b7e6e32a4cc6c076
work_keys_str_mv	AT amiraisaac amphiregulinasanoveldiagnosticandprognosticbiomarkerofhepatocellularcarcinomabeforeandafterlocoregionaltreatment AT sherifmounirmohamed amphiregulinasanoveldiagnosticandprognosticbiomarkerofhepatocellularcarcinomabeforeandafterlocoregionaltreatment AT osamaashrafahmed amphiregulinasanoveldiagnosticandprognosticbiomarkerofhepatocellularcarcinomabeforeandafterlocoregionaltreatment AT ahmedgamalmohamedhassan amphiregulinasanoveldiagnosticandprognosticbiomarkerofhepatocellularcarcinomabeforeandafterlocoregionaltreatment AT hanysamirrasmy amphiregulinasanoveldiagnosticandprognosticbiomarkerofhepatocellularcarcinomabeforeandafterlocoregionaltreatment
_version_	1718429471439060992

Amphiregulin as a novel diagnostic and prognostic biomarker of hepatocellular carcinoma before and after locoregional treatment

Ejemplares similares